AbbVie jumps into PD-1xVEGF bispecific race, pays $650M upfront to RemeGen
艾伯维加入PD-1×VEGF双特异性赛道，向荣昌生物支付6.5亿美元预付款

AbbVie is kicking off the JP Morgan Healthcare Conference with a deal in one of oncology’s hottest fields.
艾伯维以一笔交易拉开杰富瑞医疗保健大会的序幕，领域正位于肿瘤学最炙手可热的赛道之一。